GAITHERSBURG, Md., Feb. 2, 2011 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (OTCBB:CMXI), (“the Company” or “Cytomedix”) a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, today announced that Martin P. Rosendale, the Company’s President and Chief Executive Officer, issued the following letter to shareholders providing a general corporate update:
